Greg Moeck, PhD

Greg Moeck, PhD is an accomplished microbiologist with 25 years of experience in the biotech and pharmaceutical industries, specializing in antibacterial drug discovery and development. He has guided products from discovery through to regulatory approval and market launch, including post-approval studies. In his previous position as Senior Vice-President, Microbiology at Venatorx Pharmaceuticals, Greg was engaged in the development of two novel, clinical-stage antibacterial agents, cefepime-taniborbactam and ceftibuten-ledaborbactam. He also held senior positions at The Medicines Company and Targanta Therapeutics, where he led cross-functional teams and contributed to the development and regulatory approval of oritavancin and meropenem-vaborbactam in the US and Europe. He is an author of 75 peer-reviewed articles, four book chapters, and the Clinical and Laboratory Standard Institute (CLSI) M23 Guideline, and he holds multiple patents on novel methods of use of antibacterial agents. Greg‘s expertise extends to productive interactions with regulatory authorities and standards-setting institutions, and he is a recognized thought leader in translational research and development to address the existential challenge of antimicrobial resistance (AMR). He obtained his PhD in Microbiology and Immunology from McGill University (Montreal, Canada) and was a Postdoctoral Research Fellow of the Ministry of Foreign Affairs, France, and of the Natural Sciences and Engineering Research Council, Canada for his research on nutrient uptake systems and interactions in the gram-negative bacterial cell envelope as targets for drug discovery. He is active in professional service as Editorial Board member of the American Society for Microbiology (ASM) journal Case Reports (2024-2026), member of the Vivli AMR Register Steering Committee, Advisor to the CLSI Antimicrobial Susceptibility Testing (AST) Subcommittee (2016-2024), member of the Program Committee of the ASM/European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance (Porto, Portugal, 2024), and ad hoc reviewer for several scientific journals on antimicrobial agents research and development.